Thyroid Dysfunction After Intensity-Modulated Radiotherapy and PD⁃1 Inhibitor Treatment for Locally Advanced Nasopharyngeal Carcinoma

• DOI: 10.2147/tcrm.s489899
• Publication Date: 2025-01-06T06:05:11Z
• Authors: Kai Shang; Qianyong He; Xinyu Xu; Xunyan Luo; Chaofen Zhao; Lina Liu; Zhuoling Li; Yuanyuan Li; Feng Jin

Purpose: Analyze the incidence and risk factors of thyroid dysfunction in patients with advanced nasopharyngeal carcinoma (LA-NPC) after intensity-modulated radiotherapy (IMRT) PD⁃1 inhibitor treatment their relationship efficacy prognosis. Methods: Eighty-five LA-NPC treated IMRT PD-1 inhibitors were retrospectively collected from March 1, 2019, to May 30, 2022. The combination therapy was analyzed. Kaplan–Meier method used analyze between patient Logistic regression analysis screen independent for dysfunction. Results: As data cutoff (May 31, 2024), median follow-up time 27.8 months (range: 25.6 32.0 months). onset 8.26 months. is 47.06% (40/85), clinical hypothyroidism being main cause at an rate 28.24% (24/85) hyperthyroidism 3.53% (3/85). grade 1 immune-related adverse events (irAEs) 29.41% (25/85), 2 irAEs 17.65% (15/85). Patients had longer overall survival, progression-free distant metastasis-free survival both one two years compared normal function, but difference not statistically significant (p > 0.05). Multivariate logistic showed that pretreatment lactate dehydrogenase (LDH) = 0.079) predictor immunotherapy LA-NPC. Conclusion: study found addition increases shortens chemoradiotherapy. Pretreatment LDH may serve as factor patients. Keywords: carcinoma, IMRT, inhibitor, dysfunction,